Research & Development

Can Emory's New Medicines Center Transform Drug Discovery?
Research & Development Can Emory's New Medicines Center Transform Drug Discovery?

In a world where the journey from scientific discovery to life-saving treatment often spans decades, Emory University in Atlanta, Georgia, is taking bold steps to accelerate this process with the launch of its Center for New Medicines (CNM). Established just last year, this pioneering initiative

5 Biotech Stocks to Watch for Key Trial Data in September 2025
Research & Development 5 Biotech Stocks to Watch for Key Trial Data in September 2025

As the biotechnology sector continues to drive innovation in healthcare, September stands out as a critical month for several companies on the cusp of releasing pivotal clinical trial data that could reshape their futures. These upcoming announcements might serve as major catalysts, potentially

Patient Safety Crisis Persists at Saint Vincent Hospital
Research & Development Patient Safety Crisis Persists at Saint Vincent Hospital

In a troubling development for healthcare in Worcester, Massachusetts, Saint Vincent Hospital, operated by a prominent for-profit hospital system based in Texas, continues to grapple with severe patient safety issues that have sparked widespread concern among staff and regulators alike. Nurses and

New Blood Test Revolutionizes Early Ovarian Cancer Detection
Research & Development New Blood Test Revolutionizes Early Ovarian Cancer Detection

Imagine a world where a silent, deadly disease like ovarian cancer, which affects thousands of women each year, could be caught in its earliest stages with just a simple blood draw, offering hope for timely intervention. This devastating illness, often striking women over 50, frequently goes

How Does Aptamer Group's New Service Transform Biomarker Discovery?
Research & Development How Does Aptamer Group's New Service Transform Biomarker Discovery?

In the rapidly evolving landscape of biomedical research, the quest for precise and efficient tools to identify disease-specific indicators has become a cornerstone of innovation, particularly as the global market for biomarkers surges past $62 billion. Aptamer Group, a company listed on the London

Eli Lilly Advances Orforglipron in Oral Obesity Drug Race
Research & Development Eli Lilly Advances Orforglipron in Oral Obesity Drug Race

In a remarkable leap forward for obesity treatment, Eli Lilly has revealed significant strides with orforglipron, an innovative oral GLP-1 receptor agonist targeting both obesity and diabetes. The announcement on August 26 showcases results from a pivotal Phase 3 clinical trial that have ignited

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later